Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients

BMC Cancer

Research Article

Jianrong He¹  Xiaosong Chen¹  Siji Zhu¹  Yafen Li¹  Kunwei Shen¹  Ou Huang¹  Weiguo Chen¹  Jiayi Wu¹  Li Zhu¹  Xiaolong Jin²  Xiaochun Fei²  David H. Garfield³ 

[1] Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin Er Road, 20025, Shanghai, China;Department of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China;University of Colorado Comprehensive Cancer Center, 80045, Aurora, CO, USA;

关键词: Breast cancer;    Core needle biopsy;    Ki67 change;    Molecular subtype;    Surgery time interval;   

DOI  :  10.1186/s12885-015-1853-1

 received in 2014-11-10, accepted in 2015-10-27,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundTo investigate the accuracy of core needle biopsy (CNB) in evaluating breast cancer estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 status and to identify factors which might be associated with Ki67 value change after CNB.MethodsA retrospective study was carried out on 276 patients with paired CNB and surgically removed samples (SRS). Clinico-pathological factors as well as the surgery time interval (STI) between CNB and surgery were analyzed to determine whether there were factors associated with Ki67 value change after CNB. Five tumor subtypes were classified as follows: Luminal A, Luminal B-HER2-, Luminal B-HER2+, Triple Negative (TN), and HER2+. Ki67 value change was calculated as SRS minus CNB.ResultsMean STI after CNB was 4.5 (1-37) days. Good agreement was achieved for ER, PR, and HER2 evaluation between CNB and SRS. However, Ki67 expression level was significantly higher in SRS compared with CNB samples: 29.1 % vs. 26.2 % (P < 0.001). Both univariate and multivariate analysis demonstrated that STI and molecular subtype were associated with a Ki67 change after CNB. Luminal A tumors experienced more Ki67 elevation than Luminal B-HER2- diseases (6.2 % vs -0.1 %, P = 0.014). Patients with longer STI after CNB had a higher Ki67 increase: -1.1 % within 1-2 days, 2.1 % with 3-4 days, and 5.6 % more than 4 days, respectively (P = 0.007). For TN and HER2+ tumors, the Ki67 change was apt to be 0 with STI ≤ 4 days, while a >7 % Ki67 increase was noticed in patients with STI ≥ 5 days.ConclusionCNB was accurate in evaluating ER, PR, HER2, and molecular subtype status. Ki67 value significantly increased after CNB, which was associated with STI and molecular subtype. Further translational research needs to consider Ki67 changes following CNB among different breast cancer molecular subtypes.

【 授权许可】

CC BY   
© Chen et al. 2015